-
Briacell Therapeutics NasdaqCM:BCTX BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Location: Bellevue Centre, West Vancouver, BC, V7T 2X1, Canada | Website: https://briacell.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
7.371M
Cash
5.014M
Avg Qtr Burn
-5.499M
Short % of Float
5.47%
Insider Ownership
7.86%
Institutional Own.
11.67%
Qtr Updated
01/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bria-IMT™ (SV-BR-1-GM) Details Breast cancer | Phase 3 Data readout | |
Bria-OTS™ + tislelizumab Details Breast cancer, Cancer | Phase 1/2 Data readout | |
Bria-PROS+ Details Cancer, Prostate cancer | IND Submission |